In a recent authoritative review discussing immunotherapy in T1D, the authors proposed targeting of cytokine antagonists in the prevention of islet autoimmunity, including interleukin (IL)-6, IL-8 and tumor necrosis factor-α (TNF-α) and agonist targets, such as IL-2 and IL-10 [76]. Here, TNF is linked to type 1 diabetes mellitus.